The COVID-19 pandemic has been raging worldwide since its outbreak in December 2019. A recent study by a university in Hong Kong discovered that the composition of gut microbiota in coronavirus patients is concordant with disease severity. Patients had higher numbers of ‘bad bacteria’ and lacked certain ‘good bacteria’ known to regulate their immune system. What is worse is that an abnormal gut microbiota (dysbiosis) persists after clearance of the virus, which could contribute to lingering symptoms known as ‘Long COVID’.
Long COVID, known as post-COVID syndrome, are signs and symptoms that develop during or following an infection including COVID-19 which continue for more than 12 weeks and are not explained by an alternative diagnosis. The five most common symptoms are fatigue, poor memory, insomnia, breathlessness, and hair loss.
Early this year, results of a study by the Faculty of Medicine at The Chinese University of Hong Kong (CUHK Medicine) suggested gut microbiome may influence the severity of COVID-19 as well as the magnitude of the immune response to the infection. Bad bacteria including Ruminococcus gnavus, Ruminococcus torques and Bateroides dorei species had been found more in infected patients than uninfected. Similarly, they had less ‘good bacteria’ that can regulate immune system response. Even though the virus had been cleared from their bodies, the number of ‘good bacteria’ collected in samples up to 30 days after remained low.
The balance of beneficial and harmful microbes in our gut is of utmost importance. An optimal composition of good bacteria can be identified using big data and proprietary machine learning algorithms that can accurately predict disease risk and identify specific bacteria strains that correlate with health.
G-NiiB ‘Immunity +’ is a unique microbiome immunity formula containing live freeze-dried ‘good’ bacteria with patented microencapsulation technology from Italy, and heat-resistant prebiotics to replenish beneficial microbes in the human gut. Using our proprietary database of over 10,000 subjects, big data analysis and machine learning algorithms, G-NiiB Immunity+ was formulated with an optimized 3+3 best ratio of live good bacteria and prebiotics to provide the BEST result and achieve our health goal.
G-NiiB has obtained exclusive patent* licensing from the Chinese University of Hong Kong. G-NiiB is a trademark of GenieBiome, a leading microbiome biotechnology start-up founded by professors from The Chinese University of Hong Kong.
Delivery in Singapore: https://bit.ly/3eXZ1h7
Delivery in Malaysia: https://bit.ly/3wZUGAl